Related Experiment Video
Updated: Jul 7, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Oncogenic potential of BRAF versus RAS
Cara L Benjamin1, Honnavara N Ananthaswamy
1Department of Immunology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Cancer Letters
|February 19, 2008
Summary
Mutant BRAF(V600E) shows weaker oncogenic potential than mutant RAS, cooperating with specific p53 mutations in cancer development. This study compares BRAF and RAS oncogene cooperation with p53 variants in transformation.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Mutations in the ERK pathway, particularly in RAS and BRAF genes, are common in human cancers.
- RAS and BRAF mutations are typically mutually exclusive, suggesting distinct oncogenic roles.
- The interaction between oncogenes and tumor suppressor genes like p53 is crucial for cancer initiation.
Purpose of the Study:
- To compare the relative oncogenic potential of BRAF(V600E) and RAS (H-RAS and N-RAS) oncogenes.
- To investigate the cooperative effects of these oncogenes with different p53 mutations in cellular transformation.
- To elucidate the mechanisms underlying oncogenic transformation in the context of ERK pathway mutations.
Main Methods:
- Transfection of mouse embryonic fibroblasts (MEFs) with BRAF(V600E), H-RAS(G12V), or N-RAS(Q61R) oncogenes.
- Utilizing MEFs with different p53 statuses: p53 knockout (p53(-/-)), p53(R172H), and p53(R172P).
- Assessing cellular transformation through focus formation assays, in vitro growth, anchorage-independent growth, and in vivo tumorigenesis.
Main Results:
- BRAF(V600E), H-RAS(G12V), and N-RAS(Q61R) induced foci in p53(-/-) and p53(R172H) MEFs, but not in p53(R172P) MEFs.
- BRAF(V600E) demonstrated lower potency compared to RAS oncogenes, indicated by fewer and smaller foci.
- In vitro and in vivo studies confirmed the transformed phenotype and tumorigenic potential, highlighting differential cooperation with p53 variants.
Conclusions:
- Mutant BRAF(V600E) is less oncogenic than mutant RAS.
- Both BRAF and RAS oncogenes cooperate with p53(-/-) and p53(R172H) but not p53(R172P) in oncogenic transformation.
- These findings provide insights into the differential roles of BRAF and RAS in cancer development and their interaction with tumor suppressor pathways.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...